Table 3.
Treatment difference between evolocumab vs placebo for lipid variables
| Variable | Week 12 | Mean of weeks 10 and 12 | ||
|---|---|---|---|---|
| Lipid efficacy, mean (95% CI) treatment difference | ||||
| Change from baseline in LDL-C, % | −53.1 (−57.6, −48.7) | −64.1 (−68.2, −60.1) | ||
| Achievement of LDL-C <1.81 mmol/l, % | 69.1 (60.4, 75.7) | 77.9 (70.0, 83.5) | ||
| Achievement of ≥50% reduction in LDL-C, % | 64.7 (57.7, 70.3) | 83.5 (77.7, 87.4) | ||
| Per cent change from baseline in other lipids, mean (95% CI) treatment difference | ||||
| Non-HDL-C | −46.3 (−50.4, −42.2) | −56.6 (−60.3, −52.9) | ||
| ApoB | −42.1 (−46.1, −38.1) | −52.5 (−56.1, −48.9) | ||
| Total cholesterol | −33.7 (−36.9, −30.6) | −41.1 (−43.9, −38.2) | ||
| Lp(a) | −32.6 (−39.6, −25.5) | −40.5 (−48.1, −32.9) | ||
| Triacylglycerol | −13.7 (−21.6, −5.8) | −19.3 (−26.0, −12.5) | ||
| HDL-C | 7.4 (4.2, 10.6) | 9.8 (7.0, 12.6) | ||
| VLDL-C | −13.3 (−20.1, −6.6) | −17.1 (−22.9, −11.2) | ||
Placebo, n=141; evolocumab, n=280
All adjusted p values for measures reported in the table were p<0.0001 for evolocumab vs placebo comparison